In this article from Mayo Clinic Proceedings, Dr. Carlos A. Jiménez-Ruiz discusses how varenicline doses can be increased for patients who don’t respond to the standard dose, with high success rates and limited adverse effects. Be sure to watch the accompanying video, in which Dr. Jiménez-Ruiz explains the results of the study and how varenicline doses can be increased.
Slide set and audio/video recording from “Pharmacotherapy for Tobacco Dependence,” a webinar held by Global Bridges on April 4, 2012, which featured Richard D. Hurt, M.D., founder and director of the Mayo Clinic Nicotine Dependence Center.
Cytisine, a partial agonist that binds with high affinity to the α4β2 nicotinic acetylcholine receptor, is a low-cost treatment that may be effective in aiding smoking cessation. This study assessed the efficacy and safety of cytisine as compared with placebo.